Theralase® Technology Effective in Virus Inactivation

June 4, 2024 – Theralase’s lead compound, Ruvidar, has been proven effective in the inactivation of various viruses. The research was completed at the laboratory of Kevin Coombs, Ph.D., University of Manitoba in conjunction with National Microbiology Laboratory and Theralase® Technologies Inc.

Theralase® Granted Canadian Cancer Vaccine Patent

April 5th, 2024, Theralase® granted Canadian patent for a new cancer vaccine titled, “Vaccine Containing Cancer Cells Inactivated by Photodynamic Treatment with Metal-Based Coordination Complexes and Immunotherapy Method Using Same”.

Theralase® to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association

V.TLT | March 26th, 2024 Toronto, Ontario – March 26th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that it is hosting Advisory Board meetings to present the latest Study II interim clinical data to its Principal Investigators (“PIs”) at the Canadian Urological Association (“CUA”) Bladder Cancer Forum and the American Urology Association (“AUA”), respectively. Study II is a Phase II clinical study that provides a Study Procedure (Study Drug activated by a Study Device) for patients diagnosed with Bacillus Calmette Guerin (“BCG”)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”). An advisory board meeting is scheduled to take place on April 12, 2024, during the Bladder Cancer Forum 2024 located in … Read More

Theralase® Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson’s Disease

V.TLT | February 12th, 2024 Toronto, Ontario – February 12th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (“PDCs“) for the safe and effective destruction of various cancers, bacteria and viruses, donated two Theralase® TLC-2400 Cool Laser Therapy (“CLT”) systems to the University of Windsor to aid in the research and development of a novel treatment for patients suffering from Parkinson’s Disease (“Parkinson’s”). Theralase® is working in collaboration with researchers at the University of Windsor, Faculty of Human Kinetics and a Windsor based chiropractor to conduct a groundbreaking clinical study into how Theralase® CLT can be used as a treatment for Parkinson’s. Theralase®’s CLT, with its super-pulsed laser technology, is one of the few technologies in the world able to non-invasively penetrate the human skull, promoting anti-inflammatory responses and stimulating … Read More

Dr. Michael Jewett Joins Theralase® to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

V.TLT | February 8th, 2024 Toronto, Ontario – February 8th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (“PDCs“) for the safe and effective destruction of various cancers, bacteria and viruses is pleased to announce that Dr. Michael Jewett has joined Theralase®, in the role of an independent consultant, to assist the Company in the completion of enrollment of patients in the Phase II Bacillus Calmette-Guérin (“BCG”)-Unresponsive Non Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”) clinical study (“Study II”). Under the terms of the consulting agreement, Dr. Jewett will be responsible for working with existing clinical study sites and helping to onboard new clinical study sites to allow Theralase® to complete enrollment and provide the primary study treatment to all 100 patients in Study II, preferably by December 31, … Read More

Theralase® Closes $CAN 1.2 Million Non-Brokered Private Placement

V.TLT | February 5th, 2024 Toronto, Ontario – February 5th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (“PDCs“) for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a non-brokered private placement offering (“Offering“) of units (“Units“). On closing, the Corporation issued an aggregate of 6,666,670 Units at a price of $CAN 0.18 per Unit for aggregate gross proceeds of approximately $CAN 1,200,000. Each Unit consists of one common share of the Company (“Common Share“) and one common share purchase warrant (“Warrant“). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of $CAN 0.25 per share for a period of 5 years following the date of issuance. The Company plans to use … Read More